The Recall Desk

Hazard

Allergic Reaction recalls

206 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
206
Critical
5
Severe
179
Most recent
2025-12-03

Of the 206 allergic reaction recalls we have scored against our rubric, 5 (2%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 179 (87%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all allergic reaction recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

101–125 of 206

  • SevereFDA (Drugs)·D-610-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dantrolene Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dantrolene Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-845-2015·2015-04-29

    Attix Pharmaceuticals Recalls Piroxicam Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling piroxicam active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Piroxicam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-677-2015·2015-04-29

    Fluconazole API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluconazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fluconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-893-2015·2015-04-29

    Sildenafil Citrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Sildenafil Citrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Sildenafil Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-827-2015·2015-04-29

    Attix Pharmaceuticals Recalls Oseltamivir Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Oseltamivir Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Oseltamivir Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-705-2015·2015-04-29

    Attix Pharmaceuticals Recalls Histamine Diphosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Histamine Diphosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Histamine Diphosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-880-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rifaximin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rifaximin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Rifaximin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-548-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bromhexine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Bromhexine HCl active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Bromhexine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-908-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfisoxazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfisoxazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Sulphafurazole (Sulfisoxazole) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-790-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methyl Folate Calcium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methyl Folate Calcium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Methyl Folate Calcium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-600-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cortisone Acetate Micronized Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cortisone Acetate Micronized active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cortisone Acetate Micronized active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-775-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mefloquine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mefloquine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Mefloquine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-555-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcipotriene Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Calcipotriene active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcipotriene active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-672-2015·2015-04-29

    Attix Pharmaceuticals Recalls Famotidine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling famotidine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Famotidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-701-2015·2015-04-29

    Attix Pharmaceuticals Recalls Guanabenz Acetate Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Guanabenz Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Guanabenz Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-681-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flunarizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flunarizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Flunarizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-510-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ambroxol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ambroxol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ambroxol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-759-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levomefolate Calcium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levomefolate Calcium API due to potential penicillin cross-contamination from inadequate facility separation. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Levomefolate Calcium or L-5-Methyltetrahydrofolate Calcium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-553-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupropion HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupropion HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Bupropion HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-733-2015·2015-04-29

    Attix Pharmaceuticals Recalls Indomethacin Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Indomethacin Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Indomethacin Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-687-2015·2015-04-29

    Attix Pharmaceuticals Recalls Fluprostenol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Fluprostenol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fluprostenol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-748-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lansoprazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of lansoprazole active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Lansoprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-621-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desonide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desonide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desonide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-928-2015·2015-04-29

    Attix Pharmaceuticals Recalls Thyroid Porcine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Thyroid Porcine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Thyroid Porcine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-915-2015·2015-04-29

    Attix Pharmaceuticals Recalls Taurolidine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of taurolidine active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Taurolidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide